Navigation Links
Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds
Date:2/8/2011

ease.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.(1)  Non-ischemic heart disease typically affects the entire heart rather than a single region and can lead to reduced pumping strength, abnormal heart rhythms and disturbances in the heart's electrical system.(2)  The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden.  MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).CONTACT:

Erik Kopp
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
2. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
3. Boston Scientific Responds to DOJ Civil Lawsuit
4. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
5. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
6. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
7. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
8. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
9. Boston Scientific to Acquire Atritech
10. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
11. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
(Date:5/19/2013)...  The non-surgical Stretta® procedure employing ... is effective in control of gastroesophageal reflux disease ... medication 10 years post-procedure, according to an independent, ... Disease Week (DDW) meeting May 18-21, 2013 in ... "The sustained improvement in GERD-HRQL scores and ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest ... it has earned a Commendable Accreditation status from ... Health is a wholly owned subsidiary of Horizon Blue ... Health Plan Accreditation is a nationally recognized program that ... plans provide to their members. Health Plan Accreditation performance ...
(Date:5/20/2013)... Science is proud to announce the publication of the ... Robert A. Weinberg. , The First Edition has ... incorporating the most important advances in the fast-growing field ... maintains all of its hallmark features admired by students, ... Biology of Cancer is a textbook for students studying ...
(Date:5/20/2013)... (HealthDay News) -- Although many hospital intensive care ... to help improve outcomes, new research suggests this ... Since one-third of teaching hospitals in the United ... a nighttime physician in the ICU, the practice ... away from hospitals with fewer resources, the study ...
(Date:5/20/2013)... departments play a growing role in the U.S. health ... admissions and serving increasingly as an advanced diagnostic center ... Corporation study. , While often targeted as the most ... an important safety net for Americans who cannot get ... the growth of health care costs, according to the ...
(Date:5/20/2013)... Nearly three out of four pregnant women experience ... a Loyola University Medical Center study has found. , ... pregnant women,s quality of life, the study found. , ... Payton Johnson was presented during the American Congress of ... Orleans. , One hundred and four pregnant women were ...
Breaking Medicine News(10 mins):Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:'The Biology of Cancer' by Robert A. Weinberg 2Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:Hospital emergency departments gaining in importance, study finds 2Health News:Hospital emergency departments gaining in importance, study finds 3Health News:72 percent of pregnant women experience constipation and other bowel problems 2
... being issued by Foundation for Taxpayer and Consumer Rights:, ... against proposed legislation that,would create a loophole in existing ... a patient,s consent. The bill, SB 1096,(Calderon), does so ... to provide health care services. Transfers of private medical,information ...
... PLYMOUTH MEETING, Pa., March 12 Four,Rivers Software ... (CMMS) for the healthcare industry and ECRI Institute,an ... improving,patient care, announce the availability of new, real-time ... alert applications., This new integration offers ...
... 12 Managed Health Care,Associates, Inc. (MHA) announces ... Member Study, the results of which will be,revealed ... 2008 in Las Vegas,Nevada., The report was ... 2007,and examined self-reported data for key operational elements ...
... , Researchers from EPFL and Caltech have made an ... The research, appearing in the March 12 issue of ... kinds of risk, notably financial risk, are often underestimated, and ... drugs) could be caused by an erroneous evaluation of risk. ...
... Hospital today announced the start of the EASE (Exhale ... trial to explore an investigational treatment that may offer ... emphysema. The study focuses on a new procedure, called ... for trapped air (one of the primary causes of ...
... of,positive tests for methamphetamine among U.S. job applicants and ... percent between 2006 and,2007. These findings, from the Quest ... trend in use of the drug by more than ... today by Quest,Diagnostics Incorporated (NYSE: DGX ), the ...
Cached Medicine News:Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 2Health News:Four Rivers Software Systems and ECRI Institute Announce New, Real-Time Interfaces to Improve Inventory Management and Patient Safety Alert and Recall Tracking 3Health News:MHA to Release Findings of Independent Long Term Care Member Study 2Health News:To bet or not to bet: How the brain learns to estimate risk 2Health News:Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers 2Health News:Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics 2Health News:Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics 3Health News:Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: